Literature DB >> 15262112

Extent of radical hysterectomy: evolving emphasis.

Mitchel S Hoffman1.   

Abstract

OBJECTIVE: As with other oncologic operations, the indications for and the technique of radical hysterectomy for cervical cancer has changed considerably since its initial conception in the late 19th century. This paper reviews the evolution of concepts concerning the extent of radical hysterectomy for cervical cancer.
METHODS: A Medline literature search was performed through looking for articles published in the English language that related to radical hysterectomy for cervical cancer. Specific subjects that were searched included technique, morbidity, and histopathologic assessment of the parametria.
RESULTS: Initial emphasis on local control and potential long-term survival gradually shifted to reduction of mortality and serious morbidity. Early refinements directed attention to the regional lymph nodes, definition of prognostic factors, and determination of the population of patients best suited for the operation. During the mid to late 20th century, a better understanding of regional and local prognostic factors helped clarify the role of adjuvant treatment following radical hysterectomy. By the mid 20th century, the mortality and serious morbidity rates had fallen substantially, and attention turned to reduction of other types of morbidity, especially urinary bladder voiding dysfunction. Reduction of much of the serious morbidity (urinary fistulas) and voiding dysfunction has been related to modifications of the extent of radical hysterectomy. Specific nerve-sparing techniques now have been described. However, maintaining full radicality continues to be emphasized at some centers.
CONCLUSION: The current primary operative approaches to stage 1B cervical cancer include full radical hysterectomy, modified radical hysterectomy followed by adjuvant therapy in selected patients, radical hysterectomy with nerve-sparing, and individualization of surgical management. Studies are needed which further elucidate the significance of parametrial micrometastases, further define and refine broadly feasible nerve-sparing techniques, and more accurately preoperatively identify low and high risk cervical tumors. Optimally, these studies will remove adjuvant treatment as a confounding variable.

Entities:  

Mesh:

Year:  2004        PMID: 15262112     DOI: 10.1016/j.ygyno.2004.05.025

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  5 in total

1.  To what extent should we perform parametrectomy in FIGO stage IB cervical cancer?

Authors:  Ali Ayhan; Eralp Başer; Polat Dursun; Asuman Nihan Haberal
Journal:  J Turk Ger Gynecol Assoc       Date:  2013-06-01

2.  Urinary biomarkers for the diagnosis of cervical cancer by quantitative label-free mass spectrometry analysis.

Authors:  Daranee Chokchaichamnankit; Kamolwan Watcharatanyatip; Pantipa Subhasitanont; Churat Weeraphan; Siriporn Keeratichamroen; Narongrit Sritana; Nuttavut Kantathavorn; Penchatr Diskul-Na-Ayudthaya; Kittirat Saharat; Juthamard Chantaraamporn; Chris Verathamjamras; Natacha Phoolcharoen; Kriangpol Wiriyaukaradecha; Nilubol Monique Paricharttanakul; Wandee Udomchaiprasertkul; Thaniya Sricharunrat; Chirayu Auewarakul; Jisnuson Svasti; Chantragan Srisomsap
Journal:  Oncol Lett       Date:  2019-04-08       Impact factor: 2.967

3.  The Landmark Series: Minimally Invasive Surgery for Cervical Cancer.

Authors:  Derman Basaran; Mario M Leitao
Journal:  Ann Surg Oncol       Date:  2020-10-30       Impact factor: 5.344

4.  A comparison of laparoscopic and abdominal radical parametrectomy for cervical or vaginal apex carcinoma and stage II endometrial cancer after hysterectomy.

Authors:  Hongyuan Jiang; Lianxi Qu; Xishi Liu; Keqin Hua; Huan Xu; Sun-Wei Guo
Journal:  JSLS       Date:  2013 Apr-Jun       Impact factor: 2.172

5.  Identification of a low risk population for parametrial invasion in patients with early-stage cervical cancer.

Authors:  Yohann Dabi; Claire Willecocq; Marcos Ballester; Xavier Carcopino; Sofiane Bendifallah; Lobna Ouldamer; Vincent Lavoue; Geoffroy Canlorbe; Emilie Raimond; Charles Coutant; Olivier Graesslin; Pierre Collinet; Alexandre Bricou; Cyrille Huchon; Emile Daraï; Bassam Haddad; Cyril Touboul
Journal:  J Transl Med       Date:  2018-06-14       Impact factor: 5.531

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.